Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.
Saved in:
| Title: | Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition. |
|---|---|
| Authors: | Dey J; Presage Biosciences, Inc, Seattle, WA, USA., Deckwerth TL; Presage Biosciences, Inc, Seattle, WA, USA., Kerwin WS; Presage Biosciences, Inc, Seattle, WA, USA., Casalini JR; Presage Biosciences, Inc, Seattle, WA, USA., Merrell AJ; Presage Biosciences, Inc, Seattle, WA, USA., Grenley MO; Presage Biosciences, Inc, Seattle, WA, USA., Burns C; Presage Biosciences, Inc, Seattle, WA, USA., Ditzler SH; Presage Biosciences, Inc, Seattle, WA, USA., Dixon CP; Presage Biosciences, Inc, Seattle, WA, USA., Beirne E; Presage Biosciences, Inc, Seattle, WA, USA., Gillespie KC; Presage Biosciences, Inc, Seattle, WA, USA., Kleinman EF; Edward F. Kleinman LLC, Pawcatuck, CT, USA., Klinghoffer RA; Presage Biosciences, Inc, Seattle, WA, USA. rich.klinghoffer@presagebio.com. |
| Source: | Scientific reports [Sci Rep] 2017 Dec 21; Vol. 7 (1), pp. 18007. Date of Electronic Publication: 2017 Dec 21. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
